BOOK
Emerging Updates of Radiation Oncology for Surgeons, An Issue of Surgical Oncology Clinics of North America, E-Book
(2017)
Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Adam Raben, is devoted to Radiation Oncology. Dr. Raben has assembled expert authors to review the following topics: Radiation Oncology Management of Stage I-III Cervix Cancer; Radiotherapy and Radiosurgery Updates for Tumors of the Central Nervous System; Advances in Treatment of Anal Cancer with Intensity Modulated Radiation Therapy; Management of Stage 1 Lung Cancer with SRS; Postoperative Radiation Management for Head and Neck Cancers; Changing Paradigm of Radiation Management of Breast Cancer; Changing Role of Radiation Therapy in Melanoma: In Situ Vaccine with PD-1 after Surgery for Stage II-IV; Brachytherapy in the Management of Prostate Cancer; Optimal Use of CMT in the Treatment of Esophagus Cancer; Updates in Radiotherapy after Postmastectomy; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Emerging Updates ofRadiation Oncology forSurgeons\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword | vii | ||
| Preface: Update of Practical Radiation Oncology Management Trends for Surgeons | vii | ||
| Update on Radiotherapy for Central Nervous System Malignancies | vii | ||
| Controversies in Postoperative Irradiation of Oropharyngeal Cancer After Transoral Surgery | vii | ||
| Updates in the Treatment of Breast Cancer with Radiotherapy | vii | ||
| Updates in Postmastectomy Radiation | viii | ||
| Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy | viii | ||
| Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer | viii | ||
| The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings | viii | ||
| Evolving Role of Radiotherapy in the Management of Rectal Carcinoma | ix | ||
| Radiotherapy for Anal Cancer: Intensity-Modulated Radiotherapy and Future Directions | ix | ||
| Radiation Oncology Management of Stage I–III Cervix Cancer | ix | ||
| Brachytherapy in the Management of Prostate Cancer | x | ||
| Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management\r | x | ||
| SURGICAL ONCOLOGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| October 2017 | xi | ||
| January 2018 | xi | ||
| April 2018 | xi | ||
| RECENT ISSUES | xi | ||
| April 2017 | xi | ||
| January 2017 | xi | ||
| October 2016 | xi | ||
| Foreword | xiii | ||
| Preface\r | xv | ||
| Update of Practical Radiation Oncology Management Trends for Surgeons\r | xv | ||
| Update on Radiotherapy for Central Nervous System Malignancies | 347 | ||
| Key points | 347 | ||
| INTRODUCTION | 347 | ||
| BRAIN METASTASES | 348 | ||
| PRIMARY BRAIN MALIGNANCIES | 350 | ||
| HIGH-GRADE GLIOMA | 350 | ||
| LOW-GRADE GLIOMA | 352 | ||
| SUMMARY | 353 | ||
| REFERENCES | 353 | ||
| Controversies in Postoperative Irradiation of Oropharyngeal Cancer After Transoral Surgery | 357 | ||
| Key points | 357 | ||
| TRANSORAL SURGERY IN OROPHARYNGEAL CANCER TREATMENT | 357 | ||
| IMPACT OF HUMAN PAPILLOMAVIRUS ON PROGNOSIS AND STAGING OF OROPHARYNGEAL CANCER | 358 | ||
| SAFETY AND ONCOLOGIC OUTCOMES OF TRANSORAL ROBOTIC SURGERY FOR OROPHARYNGEAL CANCER | 362 | ||
| CONTROVERSIES IN ADJUVANT THERAPY FOLLOWING TRANSORAL SURGERY FOR OROPHARYNGEAL CANCER | 363 | ||
| MARGIN STATUS IN THE DETERMINATION OF ADJUVANT THERAPY AFTER TRANSORAL SURGERY | 363 | ||
| EXTRACAPSULAR EXTENSION AS A RISK FACTOR AFTER TRANSORAL SURGERY | 365 | ||
| DOSE AND EXTENT OF RADIATION FIELDS AFTER TRANSORAL SURGERY | 365 | ||
| SUMMARY | 366 | ||
| REFERENCES | 366 | ||
| Updates in the Treatment of Breast Cancer with Radiotherapy | 371 | ||
| Key points | 371 | ||
| INTRODUCTION | 371 | ||
| HISTORICAL CONTEXT | 372 | ||
| CONSENSUS GUIDELINES ON MARGINS | 372 | ||
| SHORT-COURSE BREAST RADIOTHERAPY | 373 | ||
| Accelerated Partial-Breast Irradiation | 373 | ||
| Hypofractionated Whole-Breast Irradiation | 375 | ||
| REGIONAL NODAL MANAGEMENT | 376 | ||
| SUMMARY | 378 | ||
| REFERENCES | 379 | ||
| Updates in Postmastectomy Radiation | 383 | ||
| Key points | 383 | ||
| PMRT FOR 1 TO 3 POSITIVE NODES | 384 | ||
| NODE-NEGATIVE DISEASE WITH HIGH-RISK FEATURES | 386 | ||
| CONSIDERATIONS FOR POSTMASTECTOMY RADIATION AFTER NEOADJUVANT CHEMOTHERAPY | 387 | ||
| TARGET VOLUMES | 388 | ||
| POSTMASTECTOMY RADIATION THERAPY TECHNIQUES | 389 | ||
| REFERENCES | 390 | ||
| Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy | 393 | ||
| Key points | 393 | ||
| INTRODUCTION | 393 | ||
| TREATMENT OPTIONS FOR EARLY STAGE NON–SMALL CELL LUNG CANCER | 394 | ||
| DEVELOPMENT OF STEREOTACTIC ABLATIVE RADIATION THERAPY | 394 | ||
| BIOLOGIC RATIONALE FOR STEREOTACTIC ABLATIVE RADIATION THERAPY | 395 | ||
| Vascular Effects | 396 | ||
| Accelerated Repopulation | 396 | ||
| Dose Escalation | 396 | ||
| Systemic Effects | 396 | ||
| CLINICAL SERIES | 396 | ||
| Surgery versus Stereotactic Ablative Radiation Therapy | 397 | ||
| TECHNICAL CONSIDERATIONS | 398 | ||
| Nomenclature | 398 | ||
| Technical Requirements | 398 | ||
| Motion Management | 398 | ||
| Advanced Image Guidance | 399 | ||
| Planning Considerations | 399 | ||
| TOXICITY OF LUNG STEREOTACTIC ABLATIVE RADIATION THERAPY | 399 | ||
| SUMMARY | 400 | ||
| REFERENCES | 400 | ||
| Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer | 405 | ||
| Key points | 405 | ||
| EPIDEMIOLOGY | 405 | ||
| RISK FACTORS | 406 | ||
| ANATOMY | 407 | ||
| STAGING AND WORKUP | 408 | ||
| TREATMENT MODALITIES | 409 | ||
| Surgery | 409 | ||
| Systemic Therapy | 413 | ||
| Radiotherapy | 414 | ||
| TREATMENT | 415 | ||
| Early Stage Disease | 415 | ||
| Surgical Multimodality Options: Neoadjuvant Therapy | 417 | ||
| Surgical Multimodality Options: Adjuvant Therapy | 419 | ||
| Nonsurgical Multimodality Options: Definitive Chemoradiation | 420 | ||
| Metastatic Disease | 421 | ||
| SUMMARY | 422 | ||
| REFERENCES | 423 | ||
| The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings | 431 | ||
| Key points | 431 | ||
| INTRODUCTION | 431 | ||
| STAGING | 432 | ||
| ADJUVANT RADIATION THERAPY FOR PANCREATIC CANCER | 433 | ||
| NEOADJUVANT THERAPY RATIONALE: RESECTABLE PANCREATIC CANCER | 434 | ||
| NEOADJUVANT THERAPY: RESECTABLE PANCREATIC CANCER | 435 | ||
| NEOADJUVANT THERAPY: BORDERLINE RESECTABLE PANCREATIC CANCER | 438 | ||
| RADIATION TECHNIQUES: FROM TWO-DIMENSIONAL TO INTENSITY-MODULATED RADIATION THERAPY | 439 | ||
| PROTON THERAPY | 443 | ||
| PERSONALIZED TREATMENT AND FUTURE DIRECTIONS | 444 | ||
| IMMUNOTHERAPY | 445 | ||
| SUMMARY | 446 | ||
| REFERENCES | 446 | ||
| Evolving Role of Radiotherapy in the Management of Rectal Carcinoma | 455 | ||
| Key points | 455 | ||
| INTRODUCTION | 455 | ||
| FROM SURGERY ALONE TO COMBINED MODALITY THERAPY | 456 | ||
| PREOPERATIVE RADIATION THERAPY REGIMENS | 456 | ||
| ALTERNATIVE NEOADJUVANT TREATMENT STRATEGIES | 458 | ||
| NONOPERATIVE MANAGEMENT | 460 | ||
| REDUCING TOXICITY WITH ADVANCED RADIATION TREATMENT PLANNING | 461 | ||
| SUMMARY | 463 | ||
| REFERENCES | 463 | ||
| Radiotherapy for Anal Cancer | 467 | ||
| Key points | 467 | ||
| INTRODUCTION | 467 | ||
| EPIDEMIOLOGY | 468 | ||
| HISTORICAL CONTEXT | 468 | ||
| TOXICITY OF DEFINITIVE CHEMORADIOTHERAPY | 469 | ||
| INTENSITY-MODULATED RADIATION THERAPY AND TOXICITY REDUCTION | 470 | ||
| FUTURE DIRECTIONS | 472 | ||
| Dose Escalation for Locally Advanced Disease | 472 | ||
| Dose De-escalation for Early Stage Disease | 472 | ||
| Biologic and Immunotherapy | 473 | ||
| SUMMARY | 473 | ||
| ACKNOWLEDGMENTS | 473 | ||
| REFERENCES | 473 | ||
| Radiation Oncology Management of Stage I–III Cervix Cancer | 477 | ||
| Key points | 477 | ||
| INTRODUCTION | 477 | ||
| POSTOPERATIVE RADIOTHERAPY | 478 | ||
| DEFINITIVE RADIOTHERAPY | 478 | ||
| EXTERNAL BEAM TECHNIQUES | 479 | ||
| BRACHYTHERAPY BOOST TECHNIQUES | 479 | ||
| Timing of Brachytherapy | 480 | ||
| High-Dose Rate Brachytherapy Versus Low-Dose Rate Brachytherapy | 481 | ||
| Applicator Selection | 482 | ||
| Ring/ovoid and tandem | 482 | ||
| Vaginal cylinder | 483 | ||
| Interstitial brachytherapy | 483 | ||
| Imaging for Brachytherapy Treatment Planning | 484 | ||
| FUTURE DIRECTIONS | 485 | ||
| Stereotactic Body Radiotherapy | 485 | ||
| Proton Therapy | 485 | ||
| Ongoing National Trials | 485 | ||
| SUMMARY | 486 | ||
| REFERENCES | 487 | ||
| Brachytherapy in the Management of Prostate Cancer | 491 | ||
| Key points | 491 | ||
| INTRODUCTION | 491 | ||
| THE RATIONALE FOR BRACHYTHERAPY IN THE MANAGEMENT OF PROSTATE CANCER | 492 | ||
| PROSTATE BRACHYTHERAPY TECHNICAL FACTORS | 494 | ||
| CATEGORIES OF PROSTATE BRACHYTHERAPY | 495 | ||
| Low Dose Rate Brachytherapy | 495 | ||
| High Dose Rate Brachytherapy | 497 | ||
| Consideration of brachytherapy according to prostate cancer risk group stratification | 497 | ||
| Clinical Outcomes of Prostate Cancer | 498 | ||
| Brachytherapy alone | 498 | ||
| Brachytherapy in combination with external beam radiation therapy | 500 | ||
| Brachytherapy Toxicities and Quality of Life Impacts | 501 | ||
| Brachytherapy as a Salvage Treatment | 502 | ||
| Recent Developments and Future Directions | 503 | ||
| SUMMARY | 504 | ||
| REFERENCES | 504 | ||
| Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management | 515 | ||
| Key points | 515 | ||
| INTRODUCTION | 515 | ||
| ANTI–CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 THERAPY | 516 | ||
| ANTI–PROGRAMMED CELL DEATH 1 THERAPY | 517 | ||
| COMBINATION THERAPY WITH ANTI–PROGRAMMED CELL DEATH 1 AND ANTI–CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 AGENTS | 518 | ||
| RADIATION THERAPY AND IMMUNE CHECKPOINT INHIBITORS: PRECLINICAL DATA | 518 | ||
| RADIATION THERAPY AND IMMUNE CHECKPOINT INHIBITORS: SYSTEMIC CLINICAL DATA | 520 | ||
| Case Reports | 520 | ||
| Case Series | 521 | ||
| RADIATION THERAPY AND IMMUNE CHECKPOINT INHIBITORS: INTRACRANIAL CLINICAL DATA | 524 | ||
| SUMMARY | 525 | ||
| REFERENCES | 525 |